The Gut Microbiome Drives Endogenous T Cell Activation Following CAR-T Cell Therapy.
Specific gut bacteria amplify the tumor-fighting power of CAR T therapy by activating the body's own immune cells.
Using single-cell transcriptomics and 16S RNA sequencing in a syngeneic CD19+ murine lymphoma model, CAR-T cell infusion activated endogenous gut-infiltrating CD8+ T cells toward an effector phenotype and substantially altered gut microbiota composition, with bacterial composition correlated with endogenous T cell activation status and therapy response. Supplementation of specific gut bacteria (Turicibacter and Parvibactor) during CAR-T therapy enhanced endogenous CD8+ T cell activation and cytolytic capacity, improving antitumor outcomes.
What the study was
- Study design
- preclinical experimental
- Population
- syngeneic CD19+ lymphoma mouse models
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Cancer Immunology Research
Why it surfaced
Identifies specific, supplementable gut microbiome species (Turicibacter and Parvibactor) as actionable modulators of CAR-T therapy outcomes; provides a mechanistic basis for microbiome-based adjunct strategies to address variable CAR-T responses in hematological malignancies.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.